Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.

about

Chemical synthesis of tetracyclic terpenes and evaluation of antagonistic activity on endothelin-A receptors and voltage-gated calcium channels Riociguat: a novel new drug for treatment of pulmonary hypertension.Pulmonary Hypertension in the Intensive Care Unit.

P2860

Q27325371-270EA5A0-7C99-493E-AB27-1396044D49E4 Q38502798-4D568B57-2D59-41F4-B573-B948B499C7EC Q51633921-53713598-3A60-4B27-9A61-2F031102C95D

P2860

Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.

Item

http://www.wikidata.org/entity/Q38027095

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.

@en

type

Item

label

Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.

@en

prefLabel

Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.

@en

P1476

Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.

@en

P2093

Bryan M Bishop

http://www.w3.org/2001/XMLSchema#string

Samer J Khouri

http://www.w3.org/2001/XMLSchema#string

Vincent F Mauro

http://www.w3.org/2001/XMLSchema#string

P2860

Updated clinical classification of pulmonary hypertension.

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Inhaled iloprost for severe pulmonary hypertension.

Primary pulmonary hypertension. A national prospective study.

Survival with first-line bosentan in patients with primary pulmonary hypertension.

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

Sildenafil citrate therapy for pulmonary arterial hypertension.

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American Coll

Diagnosis and assessment of pulmonary arterial hypertension.

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

P304

838-855

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/J.1875-9114.2012.01114.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229160856

http://www.w3.org/2001/XMLSchema#string

P698

22806762

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy

Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.

about

P2860

P2860

Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921